Dave Ricks, President and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY) said, "In terms of business development, I don't see a change in our general approach, which is what we have said for a while, which is we see value in deploying capital on business development where we can really complement our core therapeutic areas where we are looking at acquisitions or licensing transactions that can bring products into the portfolio to drive growth for the future, and to do that with a lot of discipline on value. So, that is what I think we have been saying for years".